 | Up a level |
Journal Article
Alexander, T., Sarfert, R., Klotsche, J., Rubbert-Roth, A., Lorenz, H. -M., Rech, J., Hoyer, B., Cheng, Q., Waka, A., Taddeo, A., Kuehl, A. A., Schett, G., Burmester, G. -R., Radbruch, A., Hiepe, F. and Voll, R. E. (2014). THE PROTEASOME INHIBITOR BORTEZOMIB AMELIORATES REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE MULTI-CENTRE OBSERVATIONAL STUDY. Ann. Rheum. Dis., 73. S. 530 - 531. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060
Doerner, T., Schulze-Koops, H., Burmester, G. -R., Iking-Konert, C., Schmalzing, M., Engel, A., Kaestner, P., Kellner, H., Kurthen, R., Krueger, K., Rubbert-Roth, A., Schwenke, H., Peters, M. A. and Tony, H. -P. (2019). Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin. Exp. Rheumatol., 37 (6). S. 937 - 946. PISA: CLINICAL & EXPER RHEUMATOLOGY. ISSN 1593-098X